NMRA Neumora Therapeutics, Inc. Common Stock

XNAS 2.92 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

NMRA $2.92 —
Key stats
$2.92
52-Week Range
$0.32 – $3.65
YTD
+76.20%
Straddle Price
$4.65
P/C Vol Ratio
0.40
Market Cap
$0.1B
Open
$0.39
Day Range
$0.37 – $0.43
Volume
512,157
Prev Close
$0.38
Fair Value
+50.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.74
Cost of Equity (CAPM)14.54% (VRP-adj)
WACC10.58%
Volatility Risk Premium+556.0pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.2B
Return on Equity (TTM)-477.9%
Book / Price107.9% — banking bias active (P/B is primary)
Debt / Equity0.75
Quality Score0/6 — cyclical/struggling (5y DCF)
SMA 50$0.89 (Market Anchor value)
SMA 20 / Bollinger Mid$0.47
Bollinger Width / SMA2014027.2% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: ALKS, BIIB, NBIX (filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$1.03
Deviation
+50.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 44.4× · 3 peers
Peer EV/EBITDA n/a 0% median 19.1× · 3 peers
Peer P/B $1.67 19% median 3.9× · 3 peers
Peer P/S n/a 0% median 4.3× · 3 peers
Market Anchor (SMA50) $0.89 81% stability 85% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
63
List Date
2023-09-15
CIK
0001885522
Next Earnings
2026-11-05 (Pre-Market)
EPS Forecast
($0.19) (4 est.)
Headquarters
Watertown, MA
Homepage
https://www.neumoratx.com

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipelin…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'23'24'25'26Avg
Jan---11.83%-2.03%19.88%2.01%
Feb--15.61%-16.13%76.26%25.25%
Mar---23.82%-28.83%-39.06%-30.57%
Apr---34.79%-14.62%18.18%-10.41%
May--8.79%-7.14%-24.18%-7.51%
Jun--1.34%-1.95%-6.59%-2.40%
Jul--29.38%146.14%0.31%58.61%
Aug---8.95%10.90%-18.90%-5.65%
Sep-13.17%23.00%4.60%-55.17%-10.19%
Oct-0.82%-15.19%69.66%-28.56%*6.27%
Nov13.53%-11.01%-25.58%---7.69%
Dec38.28%8.16%-26.03%--6.80%
Total35.20%-33.97%21.23%-71.92%-12.37%
* Only 4 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.47
SMA 50: $0.89
SMA 200: $1.81
Current: $0.39
EMA 12: $0.44
EMA 26: $0.57
MACD: -0.1298 | Signal: 0.0238
BEARISH
ADX (14): 51.31
STRONG TREND
+DI: 13.00
−DI: 33.69

Momentum Oscillators

RSI (14): 28.98
OVERSOLD
Stoch %K: 36.28
Stoch %D: 38.86
Williams %R: -60.17

Volume & Volatility

BB Upper: $0.62
BB Lower: $0.31
NEUTRAL
OBV: 21,316,996
Vol SMA 20: 2,027,670
Vol ROC: -57.71%
ATR: $0.07
True Range: $0.06
HV 20: 132.6%
HV 30: 126.6%
HV 60: 102.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary Overall Assessment: NEUTRAL with confidence level (6/10)

Key Drivers:

  • Strong technical signals indicating a consolidation phase
  • Mixed news sentiment, with both positive and negative headlines contributing to the neutral assessment
  • Moderate volatility, which may indicate a low-risk trading opportunity

Primary Risks:

  • Downside risk if the stock fails to break above recent highs
  • Upside risk if the stock breaks above resistance levels

Investment Thesis: NMRA is trading within a consolidation phase, with technical signals indicating a potential breakout or breakdown. The mixed news sentiment and moderate volatility suggest a low-risk trading opportunity.

Recent News Sentiment Impact: The recent headlines have had a neutral impact on the stock price, with both positive and negative sentiments contributing to the current trading range.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Consolidation
  • Medium-term (1-3 months): Uptrend
  • Long-term (3-12 months): Bullish

Support/Resistance Levels: Key price levels include:

  • Resistance: $1.95 (upper Bollinger Band)
  • Support: $1.23 (lower Bollinger Band)

Momentum Signals: RSI interpretation: Neutral (50.42), indicating a lack of strong buying or selling pressure.

MACD signal: Bearish (MACD is below the signal line).

Bollinger Bands position: Neutral, with the stock trading within the middle band.

Volume Analysis: Volume trends suggest institutional interest and a potential breakout:

  • Volume SMA 20: $4419512.60
  • On-Balance Volume (OBV): $63767923.83

News & Sentiment Analysis

Recent Headlines Summary: The recent headlines have been mixed, with both positive and negative sentiments contributing to the current trading range.

Sentiment Assessment: Aggregate news sentiment is neutral, with 3 positive headlines and 2 negative headlines.

Catalyst Identification: No significant upcoming events or catalysts identified.

Market Narrative: The market narrative suggests a potential breakout or breakdown, with institutional interest and moderate volatility indicating a low-risk trading opportunity.

Risk & Volatility Assessment

Risk Assessment: Beta: 0.87 (moderate risk relative to the S&P 500)

Volatility Regime: Current vs historical volatility levels suggest moderate volatility.

Options Market Signals: IV rank: 17.7% (low), indicating historically low volatility.

Unusual activity:

  • Volume flow: 14 calls vs 1 puts
  • Open interest: 46 calls vs 1 puts

Downside Protection: Support levels include $1.23 (lower Bollinger Band) and $1.15 (SMA 50).

Market Context & Positioning

Sector Performance: NMRA is outperforming its sector, with a relative strength of 10.

Institutional Activity: Institutional interest is moderate, with volume trends suggesting potential buying pressure.

Correlation Analysis: The stock has a low correlation with the S&P 500 (R-squared interpretation).

Relative Valuation: NMRA is trading within a range-bound market, with a relatively low valuation.

Key Levels & Action Items

Critical Price Levels: Resistance: $1.95 (upper Bollinger Band) Support: $1.23 (lower Bollinger Band)

Breakout/Breakdown Levels: Potential breakout levels include $2.00 and $2.20. Potential breakdown levels include $1.50 and $1.40.

Time-Sensitive Catalysts: No significant upcoming events or catalysts identified.

Risk Management: Stop-loss levels should be set at $1.15 (SMA 50) and $1.05 (lower Bollinger Band).

I hope this comprehensive analysis meets the requirements!

Generated
Earnings History
9 of 10 under expected move
Avg Expected Move
52.66%
Avg Actual Move
5.38%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-03-07 Pre-Market 19.73% 3.26% 0.17x Within
2024-05-07 Pre-Market 37.22% 4.92% 0.13x Within
2024-08-06 Pre-Market 41.39% 0.25% 0.01x Within
2024-11-12 Pre-Market 17.05% 17.08% 1.00x Exceeded
2025-03-03 Pre-Market 24.04% 9.94% 0.41x Within
2025-05-12 Pre-Market 188.57% 4.47% 0.02x Within
2025-08-06 After-Close 39.31% 3.77% 0.10x Within
2025-11-06 Pre-Market 24.81% 1.53% 0.06x Within
2026-03-30 After-Close 73.83% 1.04% 0.01x Within
2026-08-14 Pre-Market 60.69% 7.51% 0.12x Within

Earnings calendar: this week’s reports with expected vs actual moves →

NMRA Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $4.65
7-DTE Move: $4.65
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 5
Put Volume: 2
P/C Volume: 0.4
BULLISH
Call OI: 11
Put OI: 2
P/C OI: 0.182
Total OI: 13

ATM Options Pricing

ATM Call: $2.45
ATM Put: $2.20
Call %: 83.8%
Put %: 75.2%

Chain Summary

Chain Volume: 811
Chain OI: 3,601
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 16th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
16%
vs own history
GEX tilt
-1.00
OI-weighted, today
Vanna tilt
-1.00
δ-sensitivity to IV
Charm tilt
+1.00
δ-decay vs time
Vanna tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 272.4% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$4.65Oct 26
Beta Analysis

Risk Metrics

Beta: 0.4190
Alpha: -119.54%
Correlation: 0.0425
R-Squared: 0.2%
Stock Volatility: 125.8%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own NMRA
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
ICONIQ Capital Family office$4.4M
0.13%
#37 of 760.0%13F
Renaissance Technologies Hedge fund
Jim Simons
$2.1M
0.00%
#1917 of 3138-9.1%13F
Citadel Hedge fund
Ken Griffin
$1.4M
0.00%
#3296 of 6285+141.3%13F
Millennium Management Hedge fund
Izzy Englander
$866K
0.00%
#2963 of 3716-81.5%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

NMRA Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 166,698,000 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

127 filers80,666,141 shares$137.48M value48.39% of float
# Filer Shares Value % of Total % of Float Period
1 Siren, L.L.C. 8,497,822 $14.45M 10.51% 5.10% 2026-06-30
2 BlackRock, Inc. Custodian 7,791,869 $13.25M 9.63% 4.67% 2026-06-30
3 SOFTBANK GROUP CORP. 6,090,301 $10.35M 7.53% 3.65% 2026-06-30
4 Vanguard Group Inc Custodian 4,539,261 $8.13M 5.91% 2.72% 2025-12-31
5 Vanguard Capital Management LLC 4,669,585 $7.94M 5.77% 2.80% 2026-06-30
6 MIC Capital Management UK LLP 4,460,700 $7.58M 5.52% 2.68% 2026-06-30
7 FMR LLC Custodian 3,498,869 $5.95M 4.33% 2.10% 2026-06-30
8 WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST 3,309,123 $5.63M 4.09% 1.99% 2026-06-30
9 Geode Capital Management, LLC Custodian 2,607,289 $4.43M 3.22% 1.56% 2026-06-30
10 ICONIQ Capital, LLC 2,559,090 $4.35M 3.16% 1.54% 2026-06-30
11 Two Sigma Investments, LP Custodian 2,244,829 $3.82M 2.78% 1.35% 2026-06-30
12 ORBIMED ADVISORS LLC 2,139,882 $3.64M 2.65% 1.28% 2026-06-30
13 Lunate Capital Ltd 2,124,143 $3.61M 2.63% 1.27% 2026-06-30
14 Boxer Capital Management, LLC 2,000,000 $3.40M 2.47% 1.20% 2026-06-30
15 JOHNSON & JOHNSON 1,849,445 $3.14M 2.29% 1.11% 2026-06-30
16 State Street Corp 1,582,119 $2.69M 1.96% 0.95% 2026-06-30
17 TUDOR INVESTMENT CORP ET AL 1,356,147 $2.31M 1.68% 0.81% 2026-06-30
18 Ikarian Capital, LLC 1,278,408 $2.17M 1.58% 0.77% 2026-06-30
19 RENAISSANCE TECHNOLOGIES LLC 1,262,304 $2.15M 1.56% 0.76% 2026-06-30
20 Affinity Asset Advisors, LLC 1,070,651 $1.82M 1.32% 0.64% 2026-06-30
21 Marshall Wace, LLP Custodian 904,458 $1.54M 1.12% 0.54% 2026-06-30
22 Vanguard Portfolio Management LLC 894,791 $1.52M 1.11% 0.54% 2026-06-30
23 Citadel Advisors LLC Custodian 828,933 $1.41M 1.02% 0.50% 2026-06-30
24 Charles Schwab Investment Management, Inc. 823,583 $1.40M 1.02% 0.49% 2026-06-30
25 Northern Trust Corp Custodian 800,571 $1.36M 0.99% 0.48% 2026-06-30
10 filers$9.56M notional
# Filer Notional Value % of Total Period
1 TUDOR INVESTMENT CORP ET AL $6.52M 68.21% 2026-06-30
2 Stonepine Capital Management, LLC $1.25M 13.08% 2026-06-30
3 Caption Management, LLC $776.56K 8.12% 2026-06-30
4 GROUP ONE TRADING LLC Custodian $412.93K 4.32% 2026-06-30
5 Citadel Advisors LLC Custodian $256.02K 2.68% 2026-06-30
6 Susquehanna International Group, LLP Custodian $152.15K 1.59% 2026-06-30
7 Simplex Trading, LLC Custodian $87.21K 0.91% 2026-06-30
8 Jane Street Group, LLC Custodian $46.75K 0.49% 2026-06-30
9 Wolverine Trading, LLC Custodian $39.78K 0.42% 2025-09-30
10 Walleye Capital LLC $17.00K 0.18% 2026-06-30
7 filers$2.03M notional
# Filer Notional Value % of Total Period
1 Caption Management, LLC $1.04M 51.16% 2026-06-30
2 Susquehanna International Group, LLP Custodian $564.91K 27.89% 2026-06-30
3 Citadel Advisors LLC Custodian $151.64K 7.49% 2026-06-30
4 Simplex Trading, LLC Custodian $133.96K 6.61% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $95.71K 4.73% 2026-06-30
6 Wolverine Trading, LLC Custodian $22.00K 1.09% 2025-09-30
7 Jane Street Group, LLC Custodian $21.08K 1.04% 2026-06-30

NMRA Insider Trading (Form 4)

Latest: 2026-08-21
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-21 Michael Lee Milligan See Remarks Grant (A) +175,000 opt — EDGAR
2026-08-21 Jason Duncan See Remarks Grant (A) +375,000 opt — EDGAR
2026-08-21 Paul L Berns See Remarks Grant (A) +500,000 opt — EDGAR
2026-08-21 Daljit Singh Aurora See Remarks Mixed — $1.13 -$143.2K EDGAR
2026-08-21 Joshua Pinto President & CEO Grant (A) +500,000 opt — EDGAR
2026-08-19 Daljit Singh Aurora See Remarks Mixed −34,020 $1.16 -$256.2K EDGAR
2026-05-29 David Piacquad Director Grant (A) +80,000 opt — EDGAR
2026-05-29 Matthew K Fust Director Grant (A) +80,000 opt — EDGAR
2026-05-29 Alaa Halawa Director Grant (A) +80,000 opt — EDGAR
2026-05-29 Maykin Ho Director Grant (A) +80,000 opt — EDGAR
2026-05-29 Kristina Burow Director Grant (A) +80,000 opt — EDGAR
2026-02-19 Daljit Singh Aurora See Remarks Sell (S) −6,165 $3.56 -$21.9K EDGAR
2026-02-19 Joshua Pinto President Sell (S) −5,967 $3.54 -$21.1K EDGAR
2026-02-19 Michael Lee Milligan See Remarks Sell (S) −1,436 $3.56 -$5.1K EDGAR
2026-02-19 Paul L Berns See Remarks Sell (S) −9,819 $3.51 -$34.5K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

NMRA Insider Holdings

12 insiders · @ $0.39
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Kristina Burow Director 11,934,475 $4.69M $36.43M 14 2026-05-29
2 Paul L Berns See Remarks 7,528,282 $2.96M -$57.9K 8 2026-08-21
3 Keith Crandell 10%+ Owner 6,046,907 $2.38M $258.64M 5 2025-10-29
4 ARCH Venture Fund X, L.P. 10%+ Owner 6,046,907 $2.38M $50.00M 1 2025-10-29
5 Robert A. Lenz Head of R&D 309,092 $121.4K -$1.09M 7 2025-02-20
6 Joshua Pinto President & CEO 209,950 $82.5K -$1.20M 11 2026-08-21
7 Daljit Singh Aurora See Remarks 70,435 $27.7K -$1.04M 11 2026-08-21
8 Matthew K Fust Director 27,839 $10.9K -$371.0K 6 2026-05-29
9 Michael Lee Milligan See Remarks 21,034 $8.3K -$8.5K 7 2026-08-21
10 David Piacquad Director 20,100 $7.9K $0 5 2026-05-29
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

NMRA Board & Officers

As of SEC filings through Aug 21, 2026

Directors 7

Officers 5

  • Paul L Berns · Title: Chief Executive Officer and Chairman of the Board · listed since Feb 2025
  • Joshua Pinto · President · listed since Feb 2025
  • Michael Lee Milligan · Title: Chief Financial Officer & Principal Accounting Officer · listed since Feb 2025
  • Daljit Singh Aurora · Title: Chief Operating and Development Officer · listed since May 2025
  • Jason Duncan · Title: Chief Legal and Administrative Officer · listed since Feb 2025

10% owners 18

Changes in the last 10 years (43)
Aug 21, 2026Joshua Pinto first listed as a director in an SEC filing
May 30, 2025Daljit Singh Aurora listed as Title: Chief Operating and Development Officer (previously Chief Strategy Officer) in SEC filings
Feb 18, 2025Paul L Berns first listed as Title: Chief Executive Officer and Chairman of the Board in an SEC filing
Feb 18, 2025Michael Lee Milligan listed as Title: Chief Financial Officer & Principal Accounting Officer (previously Title: SVP Finance & Principal Accounting Officer) in SEC filings
Feb 18, 2025Joshua Pinto listed as President (previously Chief Financial Officer) in SEC filings
Feb 18, 2025Jason Duncan listed as Title: Chief Legal and Administrative Officer (previously Chief Legal Officer) in SEC filings
Feb 13, 2025The company announced the departure of Henry O Gosebruch from the board in an SEC filing
Feb 13, 2025The company announced the departure of Henry O Gosebruch as President & CEO in an SEC filing
Dec 11, 2023Jason Duncan became Chief Legal Officer
Sep 21, 2023Fmr LLC reported in an SEC filing no longer being a 10% owner
Sep 14, 2023Steven Gillis became a 10% owner
Sep 14, 2023Robert Nelsen became a 10% owner
Sep 14, 2023Robert A. Lenz became Head of R&D
Sep 14, 2023Paul L Berns became a director
Sep 14, 2023Michael Lee Milligan became Title: SVP Finance & Principal Accounting Officer
Sep 14, 2023Maykin Ho became a director
Sep 14, 2023Matthew K Fust became a director
Sep 14, 2023Kristina Burow became a director
Sep 14, 2023Kristina Burow became a 10% owner
Sep 14, 2023Keith Crandell became a 10% owner
Not reported recently (3)
  • Robert A. Lenz · Last reported as Head of R&D in an SEC filing dated Feb 20, 2025
  • Carol Y. Suh · Last reported as Chief Operating Officer in an SEC filing dated Feb 16, 2024
  • Amgen Inc · Last reported as a 10% owner in an SEC filing dated Sep 19, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

NMRA Proposed Insider Sales (Form 144)

Latest: 2026-08-21
Last 30d: 0 filings  ·  Last 90d: 5 filings · $702K notice value · 1 unique filer

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Aurora Daljit Singh (5, $702K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-21 Aurora Daljit Singh Officer 41,608 $66.4K 2026-08-21 Merrill Lynch — EDGAR
2026-08-20 Aurora Daljit Singh Officer 134,452 $203.6K 2026-08-20 Merrill Lynch — EDGAR
2026-08-19 Aurora Daljit Singh Officer 61,918 $101.9K 2026-08-19 Merrill Lynch — EDGAR
2026-08-18 Aurora Daljit Singh Officer 69,149 $109.6K 2026-08-18 Merrill Lynch — EDGAR
2026-08-17 Aurora Daljit Singh Officer 146,706 $220.1K 2026-08-17 Merrill Lynch — EDGAR
2026-02-17 Pinto Joshua Officer 5,967 $21.1K 2026-02-17 Merrill Lynch — EDGAR
2026-02-17 BERNS PAUL L Officer 9,819 $34.5K 2026-02-17 Merrill Lynch — EDGAR
2026-02-17 Aurora Daljit Singh Officer 6,165 $21.9K 2026-02-17 Merrill Lynch — EDGAR
2026-02-17 Milligan Michael Lee Officer 1,436 $5.1K 2026-02-17 Merrill Lynch 10b5-1 EDGAR
2025-11-12 Aurora Family Trust Director, Officer 114,703 $307.0K 2025-11-11 Merrill Lynch 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
26 ETFs hold NMRA
25 shown · $6.25M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $2.0M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.00% $926,642 $74.6B 2026-10-23
3 SCHA Schwab U.S. Small-Cap ETF Nport 0.00% $768,934 — 2026-05-31
4 VXF Vanguard Extended Market ETF Vanguard 0.00% $671,357 — 2026-09-30
5 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.00% $403,017 $13.7B 2026-10-23
6 VTWO Vanguard Russell 2000 ETF Vanguard 0.00% $359,284 — 2026-09-30
7 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.01% $285,527 — 2026-07-31
8 IBB iShares Biotechnology ETF iShares (BlackRock) 0.00% $222,204 $10.7B 2026-10-23
9 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.01% $122,692 $1.2B 2026-10-23
10 VHT Vanguard Health Care ETF Vanguard 0.00% $118,464 — 2026-09-30
11 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $107,734 — 2026-10-23
12 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $94,200 — 2026-05-31
13 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.00% $66,410 — 2026-09-30
14 RSSL Global X Russell 2000 ETF Global X 0.00% $19,705 — 2026-10-26
15 DFMC Dimensional US Micro Cap ETF Dimensional 0.00% $6,149 — 2026-10-23
16 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $6,111 — 2026-09-30
17 IBBQ Invesco Nasdaq Biotechnology ETF Invesco 0.00% $5,220 — 2026-10-24
18 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $4,609 — 2026-10-23
19 BIB ProShares Ultra NASDAQ Biotechnology ProShares 0.00% $2,948 — 2026-10-26
20 IBRN iShares Neuroscience and Healthcare ETF iShares (BlackRock) 0.05% $2,871 $6.3M 2026-10-23
21 ITWO ProShares Russell 2000 High Income ETF ProShares 0.00% $2,338 — 2026-10-26
22 URTY ProShares UltraPro Russell2000 ProShares 0.00% $1,793 — 2026-10-26
23 UWM ProShares Ultra Russell2000 ProShares 0.00% $1,259 — 2026-10-26
24 AVTM Avantis Total Equity Markets ETF Avantis 0.00% $388 $771.8M 2026-10-23
25 HDG ProShares Hedge Replication ETF ProShares 0.00% $50 — 2026-10-26
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.33
TTM Revenue
—
TTM Net Income
$-222.39M
TTM Op. Cash Flow
$-193.40M
Quarterly figures (11 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31—$-53.46M$-0.30$-46.40M
Q4 '252025-12-31—$-59.45M$-0.35$-47.95M
Q3 '252025-09-30—$-56.76M$-0.35$-46.63M
Q2 '252025-06-30—$-52.73M$-0.33$-52.40M
Q1 '252025-03-31—$-68.06M$-0.42$-59.45M
Q4 '242024-12-31—$-58.82M$-0.37$-50.34M
Q3 '242024-09-30—$-72.55M$-0.45$-33.48M
Q2 '242024-06-30—$-58.70M$-0.37$-55.38M
Q1 '242024-03-31—$-53.72M$-0.34$-43.73M
Q4 '232023-12-31—$-108.73M$-0.04$-56.03M
Q3 '232023-09-30—$-53.03M$-1.14$-47.77M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-07
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.93
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-314.6%
ROA
-144.5%
Div Yield
0.00%
FCF Yield
-295.28%
Debt/Equity
0.75
Current Ratio
—
Market Cap
$65.50M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
6.69M
SI % of Float
8.18%
Days to Cover
2.69
Short Vol Ratio
74.0%
Free Float
81.80M
Float %
44.2%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-05-29